Dr. Sanjay Singh is the Chief Executive Officer, Gennova Biopharmaceuticals Limited, a subsidiary of
Emcure
Pharmaceuticals. He has been associated with Gennova since 2006.
At Gennova, his scientific expertise has led to several innovations to treat life-threatening diseases
and he
has been at the fore-front for developing India’s first mRNA vaccine for COVID-19.
Prior to joining Gennova, he worked with the National Institute of Health (NIH), USA where he headed the
Antigen Research Section. He has won numerous awards from the US Department of Human and Health
Services, some
of which include ‘Special Act or Service Award’ in 2005 and ‘Staff Recognition Award, NIAID/NIH’ in
2004.
Dr. Singh completed his graduation and post-graduation in Science (Biochemistry) from the Lucknow
University
and is a Ph.D. in Biochemistry from the Central Drug Research Institute, Lucknow.